PubMed Health⌕ Search

Biomedical subjects

M Sinclair

Publications and source records attributed to M Sinclair.

At least 19 recordsLinked to original sources
PubMed1992

Cardiac surgery: moving away from intensive care.

OBJECTIVE: To evaluate outcome in patients managed outside an intensive care unit after open heart surgery. BACKGROUND: The high cost of cardiac surgery is mainly due to the needs of traditional postoperative care. The requirements for intensive care and treatment has decreased with improvements in techniques of cardiac surgery and anaesthesia. In this setting the need to continue to depend on intensive care units for the recovery of cardiac surgical patients is questionable on clinical and economic grounds. DESIGN: Postoperative outcome in 245 patients over a four month period was studied prospectively. PATIENTS: Mean age of the patients was 63.2 years. They underwent a wide variety of operative procedures. Ninety percent of them recovered in a dedicated three bed cardiac surgical recovery area where the management protocol led to rapid extubation and step down in dependency care. RESULTS: Median time for ventilatory support was 90 minutes after transfer to the area. Only five patients were subsequently admitted to the general intensive care unit for prolonged respiratory and cardiac support. Ten patients were electively admitted to the general intensive care unit. Two deaths occurred in hospital in this group (0.8%). Four patients were ventilated for 24 hours in the recovery area itself and made an uncomplicated recovery. CONCLUSION: This study confirms that over 90% of patients undergoing cardiac surgery would recover safely and be treated effectively in a more economical area than intensive care.

Adult↗
PubMed1991

A revised weight loss program in Manitoba Native communities.

In summary a culturally relevant weight loss program should consider the factors of age, education, economics and community. If these factors are not considered then it is the opinion of the author that programs involved with health may not succeed on a reserve.

Health Promotion↗
PubMed1990

A combined physical and genetic map of Pseudomonas aeruginosa PAO.

A combined physical and genetic map of Pseudomonas aeruginosa PAO was constructed by pulsed-field gel electrophoresis and Southern hybridization using cosmid clones from a genomic library carrying known genes. A total of 37 SpeI restriction fragments have been mapped on the 5862 kb genome, and fragment contiguity demonstrated by hybridization with clones from a SpeI junction fragment library and fragments obtained by partial SpeI digestion, both derived from the P. aeruginosa PAO chromosome.

Blotting, Southern↗
PubMed1989

Dry bed training.

Explore the source record for details and available documents.

Behavior Therapy↗
PubMed1988

The Meisenheimer complex of glutathione and trinitrobenzene. A potent inhibitor of the glutathione S-transferase from Galleria mellonella.

1. The Meisenheimer complex formed between reduced glutathione and 1,3,5-trinitrobenzene is characterised by an extinction coefficient at 470 nm of 20400 and by an association constant at pH 9.18 of 42 l.mol-1. 2. Trinitrobenzene is a moderately good inhibitor of the glutathione S-transferase from larvae of the moth Galleria mellonella. It acts by competition with the electrophilic substrate. At pH 7.4, it has a Ki value of 10 microM. Its mode of inhibition with respect to GSH appears to be non-competitive. 3. At pH values below 9.0, the Meisenheimer complex does not appear to be formed in sufficient quantity to give significant inhibition of the enzyme. At pH 9.0 and at GSH concentrations greater than 1 mM, the inhibition of the enzyme became markedly non-hyperbolic. This was attributed to the inhibitory action of the Meisenheimer complex. The complex appears to act also by competition with the electrophilic substrate and its Ki is calculated to be 1.7 X 10(-7) M.

Animals↗
PubMed1985

The effects of thromboxane antagonism on the transit time of platelets through the spleen.

The spleen is well-known as a site for platelet pooling, although the mechanisms controlling intrasplenic platelet transit are essentially unknown. We tested the possibility that thromboxane A2 might be involved in this control by measuring intrasplenic platelet transit time in 10 subjects receiving a specific thromboxane A2 receptor antagonist (AH23848B; 70 mg; Glaxo Group Research Ltd), in 10 receiving aspirin (300 mg) plus dipyridamole (75 mg), and in 9 receiving placebo. All doses were administered 3 times daily commencing 4 days prior to transit time measurement. Mean intrasplenic platelet transit time was measured by monitoring the kinetics of equilibration of 111In radiolabelled platelets between blood and spleen following intravenous injection. There was no difference between the mean transit time in the 3 groups of subjects, lending no support to the hypothesis that thromboxane A2 is involved in the control of platelet traffic through the spleen.

Aged↗